{
  "content": "Diagnosis\n\t1. Prostate adenocarcinoma with mixed features, left zone predominant\n\tDate of diagnosis\n\tJanuary 2024\n\n\tTreatment aim\n\tCurative\n\n\tSummary of completed treatment and relevant dates\n\n\tSurgery\n\tNot indicated - locally advanced at presentation\n\n\tRadiotherapy\n\t15 Feb 2024 - 22 Mar 2024\n\tRadical IMRT 74Gy in 37 fractions to prostate and pelvic nodes\n\n\tSystemic therapy\n\tLuteinizing hormone-releasing hormone (LHRH) analogue commenced 12 Jan 2024\n\tBicalutamide 50mg daily 12-26 Jan 2024\n\tOlaparib 300mg BD commenced 1 Apr 2024 following confirmation of ATM mutation\n\n\tClinical studies\n\tNone\n\n\tCurrent disease status\n\tStable biochemical response\n\n\tCurrent issues\n\tGrade 2 fatigue\nMild gastrointestinal symptoms\n\n\tSummary of consultation\n\tReviewed today for assessment of tolerance to Olaparib therapy. PSA has decreased from 89.4 to 12.3 since January. Performance status remains 1. Main side effects are fatigue and intermittent nausea, both manageable with current supportive measures. Blood counts stable with mild anaemia (Hb 118). No dose modifications required.\n\n\tFurther investigations\n\tPSA and FBC/U&E in 4 weeks\n\n\tMedication prescribed\n\tContinue Olaparib 300mg BD\nContinue LHRH analogue\n\n\tFollow up\n\tNext oncology follow up in 4 weeks with blood results\n\n\tRequired GP actions\n\tNone required\n\n\tSummary of information given to patient\n\tDiscussed stable disease status and good tolerability of current treatment. Patient understands to contact if side effects worsen.",
  "output": {
    "primary_cancer": {
      "site": "prostate, left zone predominant",
      "year": 2024,
      "month": 1,
      "metastases": "pelvic nodal involvement",
      "other_stage": "Stage IIIC",
      "histopathology_status": "adenocarcinoma with mixed features",
      "biomarker_status": "ATM mutation positive, Initial PSA 89.4",
      "cancer_timeline": [
        {
          "type": "laboratory_finding",
          "value": "Initial PSA 89.4",
          "year": 2024,
          "month": 1
        },
        {
          "type": "treatment_systemic_start",
          "value": "Started LHRH analogue",
          "year": 2024,
          "month": 1
        },
        {
          "type": "treatment_systemic_start",
          "value": "Started Bicalutamide 50mg daily",
          "year": 2024,
          "month": 1
        },
        {
          "type": "treatment_systemic_change",
          "value": "Completed Bicalutamide course",
          "year": 2024,
          "month": 1
        },
        {
          "type": "treatment_radiotherapy",
          "value": "Completed radical IMRT 74Gy in 37 fractions to prostate and pelvic nodes",
          "year": 2024,
          "month": 3
        },
        {
          "type": "treatment_systemic_start",
          "value": "Started Olaparib 300mg BD following confirmation of ATM mutation",
          "year": 2024,
          "month": 4
        },
        {
          "type": "laboratory_finding",
          "value": "PSA decreased to 12.3",
          "year": 2024,
          "month": 4
        }
      ]
    },
    "patient_facts": [
      {
        "type": "performance_status",
        "value": "Performance status 1"
      },
      {
        "type": "current_symptom",
        "value": "Grade 2 fatigue"
      },
      {
        "type": "current_symptom",
        "value": "Intermittent nausea"
      },
      {
        "type": "investigation_finding",
        "value": "Mild anaemia with Hb 118"
      }
    ],
    "status_updates": [
      {
        "type": "clinical_summary",
        "value": "Locally advanced prostate cancer with nodal involvement showing good biochemical response to combined modality treatment including LHRH analogue, radiotherapy and targeted therapy with Olaparib"
      },
      {
        "type": "latest_treatment_toxicity",
        "value": "Grade 2 fatigue and mild nausea, both manageable with supportive care"
      },
      {
        "type": "update_to_treatment",
        "value": "Continuing Olaparib 300mg BD and LHRH analogue with no dose modifications required"
      },
      {
        "type": "planned_investigation",
        "value": "PSA and FBC/U&E in 4 weeks"
      },
      {
        "type": "follow_up_referral",
        "value": "Oncology review in 4 weeks with blood results"
      }
    ]
  }
}